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Résumé en
anglais
Medicines for the treatment of rare diseases frequently do not attract the interest of
the pharmaceutical industry, and hospital pharmacists are thus often requested by
physicians to prepare personalized medicines. Tuberous Sclerosis Complex (TSC) is a
rare disease that causes disfiguring lesions named facial angiofibromas. Various
topical formulations of rapamycin (= sirolimus) have been proved effective in treating
these changes in small case series. The present study provides for the first time
characterization of a 0.1% rapamycin cream formulation presenting good rapamycin
solubilisation. The first step of the formulation is solubilisation of rapamycin in
Transcutol®, and the second step is the incorporation of the mixture in an oil-in-
water cream.
A HPLC stability-indicating method was developed. Rapamycin concentration in the
cream was tested by HPLC and confirmed that it remained above 95% of the initial
concentration for at least 85 days, without characteristic degradation peaks. The
preparation met European Pharmacopoeia microbial specifications throughout
storage in aluminum tubes, including when patient use was simulated. Odour,
appearance and colour of the preparation were assessed and no change was
evidenced during storage. The rheological properties of the cream also remained
stable throughout storage.
To conclude, we report preparation of a novel cream formulation presenting
satisfactory rapamycin solubilisation for the treatment of TSC cutaneous
manifestations, with stability data. The cream is currently being used by our patients.























Publié sur Okina (http://okina.univ-angers.fr)
